Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B

Inventors

Cheng, Shi-Yuan • Hu, Bo • Huang, Tianzhi

Assignees

Northwestern University

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12576088-B2

Patent

Publication Date

2026-03-17

Expiration Date


Abstract

Disclosed are methods and compositions for treating cell proliferative diseases and disorders such as cancers. Particularly disclosed are methods and composition for treating cancers such as glioblastoma by administering a therapeutic agent that inhibits the biological activity of the autophagy related 4B cysteine peptidase (ATG4B) protein in conjunction with additional therapeutic agents or treatments.

Core Innovation

The invention relates to methods for treating cancer in a subject in need thereof by administering an ATG4B inhibitor and an mTOR inhibitor. The ATG4B inhibitor inhibits the biological activity of ATG4B, where the ATG4B inhibitor comprises NSC 185058 (CAS 39122-38-8), N-pyridin-2-yl-pyridine-2-carbothioamide, or a salt thereof. The mTOR inhibitor inhibits the biological activity of mTOR and is administered as a separate therapeutic agent.

The combination treatment with an ATG4B inhibitor and an mTOR inhibitor provides enhanced cancer cell death and improved survival of the subject compared with treatment with either therapeutic agent alone. The documented approach is described in terms of inhibiting ATG4B-mediated autophagy to enhance cytotoxic treatment, with the mechanistic rationale including reduced LC3 processing and autophagy markers when ATG4B is inhibited.

The described treatment framework is particularly associated with glioblastoma (GBM) and can include additional modalities as further disclosed in dependent claims, including radiotherapy and alkylating agents such as temozolomide. The document further describes combination regimens in which ATG4B inhibition is paired with mTOR inhibition to reduce autophagy induction and to improve tumor growth control and survival outcomes in described models, including TMZ-resistant patient-derived xenograft settings.

Claims Coverage

The document provides one independent claim (clm-00001). It centers on a combination treatment that includes an ATG4B inhibitor and a separate mTOR inhibitor, with a stated requirement that the combination yields enhanced cancer cell death and survival compared to either agent alone.

Treating cancer with dual inhibition of ATG4B and mTOR

A method for treating cancer in a subject comprises administering a therapeutic agent that inhibits the biological activity of ATG4B (comprising NSC 185058, CAS 39122-38-8, N-pyridin-2-yl-pyridine-2-carbothioamide, or a salt thereof) and administering a separate therapeutic agent that inhibits the biological activity of mTOR, wherein combination treatment provides enhanced cancer cell death and survival than either therapeutic agent alone.

Overall claim coverage is directed to dual-pathway targeting via ATG4B inhibition together with mTOR inhibition as separate therapeutic agents, with the key inventive requirement that the combination produces enhanced cancer cell death and improved subject survival relative to monotherapy.

Stated Advantages

Enhanced cancer cell death compared with treatment with either therapeutic agent alone.

Improved survival of the subject compared with treatment with either therapeutic agent alone.

Documented Applications

Treating cancer in a subject, including glioblastoma.

Combination cancer treatment with radiotherapy and/or alkylating agents such as temozolomide, as further described in dependent claim refinements.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.